NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellect ...

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

She said the Food and Drug Administration recently relaxed the Risk Evaluation and Mitigation Strategies, or REMS, program for Filspari. During the first year of treatment patients need to undergo liver function monitoring every three months vs. prior requirements for every month. TRENDING: Palantir, Robinhood Earnings Due After Market's Tricky October Travere Therapeutics (TVTX) stock popped Friday — soaring into a profit-taking zone — on another sales beat from its linchpin drug, Filspari. Filspari treats ...

Key Takeaways Rigel will report Q3 2025 earnings on Nov. 4, with revenue estimated at $61.6 million.Tavalisse demand and solid sales of Rezlidhia and Gavreto are likely to have driven RIGL's revenue growth.Investors await updates on R289 and potential new guidance amid strong product momentum.Rigel Pharmaceuticals (RIGL) is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 million, while the ...

Group 1 - BridgeBio Pharma, Inc. is a commercial-stage biotechnology company focused on delivering Acoramidis for the treatment of ATTR-CM, marketed as Attruby in the US and Beyonttra in the EU and Japan [1] - Beyonttra is commercialized by Bayer, indicating a partnership that may enhance market reach and distribution capabilities for the drug [1]

Core Insights - Illumina reported revenue growth and raised its financial guidance for the second consecutive quarter [1] - CEO Jacob Thaysen acknowledged challenges from US-China export restrictions but emphasized Illumina's commitment to the market and strong global performance [1] Financial Performance - Illumina's revenue growth indicates a positive trend in financial performance [1] - The company has raised its financial guidance, suggesting confidence in future earnings [1] Market Outlook - CEO Jacob Thaysen discussed the company's outlook on "Bloomberg Markets," highlighting ongoing challenges and the company's strategic focus [1] - Despite external challenges, Illumina remains dedicated to maintaining its market position [1]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM) (“TXTM”), an emerging biotechnology company pioneering advancements in plant-based therapeutics, today released an official statement from Chief Executive Officer Mr. Dylon Du Plooy, addressing shareholders in light of the company’s continued operational and strategic progress following the removal of the Caveat Emptor designation. Message to Shareholders: Following the removal of the Caveat Emptor designation, Protext Mobility I ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Unicycive Therapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period [2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Unicycive between March 29, 2024, and June 27, 2025, following a class action complaint filed on August 15, 2025 [2][4]. - Investors are encouraged to contact the law firm for discussions regarding their legal rights and options [1][4]. Group 2: Company Performance and Regulatory Issues - The complaint alleges that Unicycive misrepresented its readiness to meet FDA manufacturing compliance requirements for its New Drug Application (NDA) for oxylanthanum carbonate (OLC) [8]. - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party vendor, leading to a significant stock price drop of over 40% [8]. - Following the issuance of a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8].

Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.ILMN shares are climbing with conviction. Watch the momentum hereThe DNA sequencing company reported adjusted earnings of $1.34 per share, beating the consensus of $1.17.The company, in its prepared remarks, said the performance reflects the momentum in the clinical markets, where sequencing consumables revenue grew at a high single-digit rate year-over-year.The sales reached $1.084 bil ...